Program
ifinatamab deruxtecan
Also written as “Ifinatamab deruxtecan”, “I-DXd” and “Ifinatamab Deruxtecan”.
In Merck’s pipeline, Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoi
. Its studies are mostly in Small Cell Lung Carcinoma · Esophageal Squamous Cell Carcinoma · Carcinoma, Non-Small-Cell Lung · Neoplasms · Lung Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 1010 open or running | phase 3since Apr 7, 2025 | Nov 14, 2019 | Jun 12, 2027phase 2 · NCT07405151 |
| Daiichi Sankyo | 66 open or running | phase 3since Jan 2, 2024 | Oct 17, 2019 | Apr 30, 2027phase 2 · NCT04145622 |
- Named in Merck’s own pipeline as
ifinatamab deruxtecan (MK-2400)
, phase 3, as of Nov 2, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- Co-developmentMerck develops it with Daiichi Sankyo, worldwide except Japan, where Daiichi Sankyo keeps the rights.Announced Oct 19, 2023 · Source: Merck, Oct 19, 2023
History and studies of Daiichi Sankyo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 17, 2019First study: phase 2 study in NeoplasmsFirst studyNCT04145622 · 247 enrolled · United States, Japan
- Jan 25, 2022Named ifinatamab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 126
- Feb 23, 2022Phase 2 study in Small Cell Lung CarcinomaNCT05280470 · 187 enrolled · United States, China, France and more
- Oct 19, 2023Merck develops it with Daiichi SankyoCo-developmentWorldwide except Japan, where Daiichi Sankyo keeps the rights · announced · Merck
- Jan 2, 2024Phase 2 study in Extensive Stage-small Cell Lung CancerNCT06362252 · 123 planned · United States, France, Japan and more
- Jan 2, 2024Phase 3 study in Small Cell Lung CarcinomaNCT06203210 · 540 planned · United States, Australia, Austria and more
- Mar 19, 2024Phase 2 study in RecurrenceNCT06330064 · 680 planned · United States, Argentina, Australia and more
- Oct 10, 2024Phase 3 study in Esophageal Squamous Cell CarcinomaNCT06644781 · 510 planned · United States, Belgium, China and more
- Oct 1, 2026Primary completion moved from 2026-09-30 to 2027-07-20Date moved laterphase 2 · +10 months · NCT06362252
Ahead
- Apr 30, 2027Primary completion: phase 2 study in NeoplasmsNCT04145622
- Jul 20, 2027Primary completion: phase 2 study in Extensive Stage-small Cell Lung CancerNCT06362252
- Jan 30, 2028Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT06203210
- Jun 1, 2028Primary completion: phase 3 study in Esophageal Squamous Cell CarcinomaNCT06644781
TargetBeta
“Ifinatamab deruxtecan is an investigational antibody-drug conjugate that consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoi”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody against the immunoregulatory protein B7-homologue 3 (B7-H3, CD276) ”NCIt, by rule
Other programs on CD276
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| risvutatug rezetecan | Hansoh Pharmaceutical Group | phase 3 | 30 |
| tambotatug pelitecan | MediLink Therapeutics (Suzhou) | phase 3 | 13 |
| Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 | CSPC Pharmaceutical Group | phase 3 | 5 |
| Anti-B7-H3 Antibody-drug Conjugate MHB088Crule | Minghui Pharmaceutical | phase 3 | 4 |
| Elfetabart Drozuntecanrule | BioNTech | phase 3 | 3 |
| Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101rule | tj-biopharma-co-ltd | phase 3 | 3 |
| Lutetium Lu 177-DOTA-Anti-B7-H3 Monoclonal Antibody RV-01rule | radiopharm-theranostics-ltd | phase 2 | 1 |
| Autologous Anti-B7-H3 CAR T-cells BCB-276rule | brainchild-bio-inc | phase 2 | 1 |
| Anti-B7-H3/CD28 Bispecific Antibody XmAb808rule | Xencor | phase 1 | 2 |
| Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034rule | ideaya-biosciences | phase 1 | 1 |
| Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001rule | neok-bio-inc | phase 1 | 1 |
| HLX316 | Fosun Pharma | phase 1 | 1 |
Studies
All 6 Daiichi Sankyo leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06644781Esophageal Squamous Cell Carcinoma · United States, Belgium, China and more | 3 | Recruiting | Jun 1, 2028 | 510 |
| NCT06330064Recurrence · United States, Argentina, Australia and more | 2 | Recruiting | Jul 25, 2028 | 680 |
| NCT06362252Extensive Stage-small Cell Lung Cancer · United States, France, Japan and more | 2 | Recruiting | Jul 20, 2027 | 123 |
| NCT06203210Small Cell Lung Carcinoma · United States, Australia, Austria and more | 3 | Recruiting | Jan 30, 2028 | 540 |
| NCT05280470Small Cell Lung Carcinoma · United States, China, France and more | 2 | Active, not recruiting | Mar 3, 2025 | 187 |
| NCT04145622Neoplasms · United States, Japan | 2 | Active, not recruiting | Apr 30, 2027 | 247 |
How it is read
Names in the registry
- “Ifinatamab deruxtecan”, 5 entries
- “I-DXd”, 3 entries
- “Ifinatamab Deruxtecan”, 3 entries
- “Ifinatamab Deruxtecan (I-DXd)”, 3 entries
- “I-DXD”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 5 studies
- Esophageal Squamous Cell Carcinoma, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Neoplasms, 2 studies
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.